Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO	Complete if Known		
CINRORMATION DISCLOSURE	Application Number	09/835,523	
STATEMENT BY APPLICANT	Filing Date	04/17/2001	
7 3 2004 8)	First Named Inventor	Yong-Qian Wu	
TINH 5 3 ton \$	Group Art Unit	1624	
(use as many sheets as necessary)	Examiner Name	Truong, Tamthom Ngo	
Sheet of 2	Attorney Docket Number	054707-0661	

U.S. PATENT DOCUMENTS						Class/subclar	
Examiner Cite No.1	U.S. Patent I			Date of Publication of	Pages, Columns, Lines, Where Relevant		
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
TNT	A1	4,801,706		WINKLEY et al.	01/31/1989	540/534	
71	A2	5,399,565		GREENWOOD et al.	03/21/1995	5147314	
1.	A3	5,670,503		KAWAI et al.	09/23/1997	514/243	
M	A4	5,798,355		STEINER et al.	08/25/1998	5147248	
at 1						11/11/	

				·F(DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	F Office		nent d Code ⁵ known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
TNI	A5	CA	2,271,837	A1	ARZNEIMITTEL WERK DRESDEN GMBH, DE	11/11/1999		
1	A6	EP	0 104 484	A1	NIPPON KAYAKU KABUSHIKI KAISHA	04/04/1984		
	A7	EP	0 450 757 🗸/	A2	GLAXO GROUP LIMITED	10/09/1991		
	A8	EP	0 778 023	A1	AMERICAN HOME PRODUCTS CORPORATION	06/11/1997		
	A9	V O	89/06535 🗸	A1	E.R. SQUIBB & SONS, INC.	07/27/1989		
	A10	WO	94/19350	A1	FUJISAWA PHARMACEUTICAL CO., LTD.	09/01/1994		
	A11	WO	99/20272 //	A1	MERCK & CO., INC.	04/29/1999		
	A12	WO	96/05180 🏏	A1	ABBOTT LABORATORIES	02/22/1996		
	A13	wo	99/462481	A1	VERTEX PHARMACEUTICALS INCORPORATED	09/16/1999		
TNT	A14	WO	98/05333	A1	MOLECUMETICS LTD	02/12/1998		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ltem (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶			
m.	A15	BALDWIN et al., "Pyrazolotriazines: a new class of tumour-inhibitory agents," J. Pharm. Vol. 18, pp. 1S-4S (May 2, 1966).				
m	A16	Borloo et al., "Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase," Letters in Peptide Science, vol. 2, pp. 198-202 (1995).				

Examiner Signature	Mem	Date Considered	3/18/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Distitute for form 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	09/835,523	
STATEMENT BY APPLICANT	Filing Date	04/17/2001	
JUN 2 3 2004)	First Named Inventor	Yong-Qian Wu	
(use as many sheets as necessary)	Group Art Unit	1624	
(use as many sheets as necessary)	Examiner Name	Truong, Tamthom Ngo	
Sheet RADE RADE of 2	Attorney Docket Number	054707-0661	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	7		
M	A17	STEINER et al., "Neurotrophic actions of nonimmunosuppresive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A," Nature Medicine, vol. 3, no. 4, pp. 421-428 (April 1997).			
•		·			

Examiner Signature	Ulm	Date Considered	3(18/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.